本季度信息
根据公告，国药集团一致药业股份有限公司（国药一致）2025年第三季度实现营业收入约183.28亿元，同比下降1.89%。经调整净利润（扣除非经常性损益后）约2.80亿元，同比下降10.42%。截至2025年第三季度末，前九个月累计营业收入约551.24亿元，同比下降2.38%；累计经调整净利润约9.23亿元，同比下降9.87%。
财报显示，前九个月经营活动产生的现金流量净额为-4.63亿元，同比降幅为136.15%。公告未披露销售及管理费用率、研发投入占比等具体成本结构指标。公告也未显示下个财报期的业绩指引或业务展望。
业务分项
公告未显示各业务板块的具体营收数据及增幅。
高管解读
公告未包含相关高管讲话内容。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.